699 reports of this reaction
1.3% of all TICAGRELOR reports
#20 most reported adverse reaction
VASCULAR STENT THROMBOSIS is the #20 most commonly reported adverse reaction for TICAGRELOR, manufactured by AstraZeneca Pharmaceuticals LP. There are 699 FDA adverse event reports linking TICAGRELOR to VASCULAR STENT THROMBOSIS. This represents approximately 1.3% of all 52,671 adverse event reports for this drug.
TICAGRELOR has an overall safety score of 85 out of 100. Patients taking TICAGRELOR who experience vascular stent thrombosis should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
VASCULAR STENT THROMBOSIS is a less commonly reported adverse event for TICAGRELOR, but still significant enough to appear in the safety profile.
In addition to vascular stent thrombosis, the following adverse reactions have been reported for TICAGRELOR:
The following drugs have also been linked to vascular stent thrombosis in FDA adverse event reports:
VASCULAR STENT THROMBOSIS has been reported as an adverse event in 699 FDA reports for TICAGRELOR. This does not prove causation, but indicates an association observed in post-market surveillance data.
VASCULAR STENT THROMBOSIS accounts for approximately 1.3% of all adverse event reports for TICAGRELOR, making it a notable side effect.
If you experience vascular stent thrombosis while taking TICAGRELOR, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.